Back to News
Market Impact: 0.3
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
Source: Business Wire
Healthcare & BiotechM&A & Restructuring
Italfarmaco and JCR entered an exclusive licensing agreement for the development and commercialization of JR-141 across the United States, Europe, and Latin America. The deal expands the companies' geographic commercialization opportunity in healthcare, though financial terms and development timelines were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- David Ellison says combined Paramount and Warner Bros. Discovery will be named Skydance
- Paramount and Warner Bros Discovery to become Skydance
- Paramount’s Warner Bros. megamerger will just be called Skydance
- David Ellison goes minimalist with his new name for his Paramount-Skydance-Warner-Bros-Discovery empire
- Your health insurance premiums may take a big jump in 2027 — here's why